Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials · 2026-11 · 38 (61)
DOI: 10.1002/adma.74760 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Materials, online erschienen am 29.08.2026. Verfasst von Yuran Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmaceutical Science, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Brain Neoplasms, Biological Products, Drug Delivery Systems. Die Arbeit nennt 394 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tour De Cure, NHMRC Investigator Grant, NHMRC Synergy Grant.
Abstract (Originalsprache)
Brain cancer remains a major global health challenge due to its high morbidity and mortality. Current standard therapies are often limited by incomplete tumor resection, systemic toxicity, and the inability to effectively penetrate the blood‐brain barrier (BBB), which restricts drug delivery to the tumor site. These challenges underscore the urgent need for innovative therapeutic strategies that can overcome these barriers and improve treatment outcomes. Biological materials encompass a diverse range of molecules, from small peptides to monoclonal antibodies, either derived from living organisms or synthetically synthesized. Unlike traditional therapies, biologics provide a more targeted approach, including specific tumor targeting, immune system modulation, and regenerating damaged cells. Although biologics offer significant promise for brain cancer treatment, major challenges associated with blood–brain and tumour barriers continue to limit their translation, and comprehensive reviews bridging therapeutic advances with delivery technologies remain scarce. While individual biologic classes have been extensively studied, a unified assessment of these modalities and their delivery optimization is still needed. This review addresses the current gap by critically examining recent advances in biologic therapies and evaluating emerging invasive and non‐invasive delivery strategies to enhance their therapeutic efficacy in brain cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Pharmaceutical Science, The University of Queensland, Brisbane, Queensland, Australia.
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
- Children's Cancer Institute at Minderoo Children's Comprehensive Cancer Centre, Sydney, New South Wales, Australia.
- Australian Centre for NanoMedicine, UNSW Sydney, Sydney, New South Wales, Australia.
- School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat
Förderung
- Tour De Cure
- NHMRC Investigator Grant
- NHMRC Synergy Grant
- Cancer Council Queensland
- Cure Cancer
Zitieren
APA
Feng, Y., Cao, Y., Kavallaris, M., Janjua, T., & Popat, A. (2026). Advanced Materials for Biologics Delivery to Brain Tumors. Advanced Materials, 38(61). https://doi.org/10.1002/adma.74760
Vancouver
Feng Y, Cao Y, Kavallaris M, Janjua T, Popat A. Advanced Materials for Biologics Delivery to Brain Tumors. Advanced Materials. 2026;38(61). doi:10.1002/adma.74760
BibTeX
@article{Feng2026,
author = {Feng, Yuran and Cao, Yuxue and Kavallaris, Maria and Janjua, Taskeen and Popat, Amirali},
title = {Advanced Materials for Biologics Delivery to Brain Tumors},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {61},
doi = {10.1002/adma.74760}
}
EUVIMED